CareDx Adds iBox Technology, Next Step Towards Artificial Intelligence in Transplant Care
BRISBANE, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced a partnership with Cibiltech, a French MedTech company that develops AI-based products for predictive medicine, to commercialize Predigraft.
Predigraft is a data analysis tool that provides an early prediction of an individual’s risk of allograft rejection and transplant loss. It was developed from Cibiltech’s proprietary software algorithm called iBox, which is built off the outcomes data from tens of thousands of transplant patients. “I see incredible value in using prognostic data alongside a measure of organ injury from non-invasive biomarkers such as AlloSure,” said Gaurav Gupta, MD, Virginia Commonwealth University. “This can give me insights that shape the care I give to my transplant patients.”
Under the agreement, CareDx holds the exclusive rights to commercialize Predigraft in the US and CareDx becomes a minority equity owner of CibilTech. The companies have also agreed to collaborate to advance the development of artificial intelligence in transplant care. CareDx and Cibiltech will be sharing demonstrations of iBox at the American Transplant Congress June 1-4, 2019 in Boston.
“We are delighted to collaborate with CareDx as it is a very promising step to bring years of work on artificial intelligence from the Paris Transplant Group to transplant patients. Our technology has been selected by numerous peer reviewed publications, and we believe that the team at CareDx is a great partner to make this available to the field of transplantation,” said Alexandre Loupy, MD, iBox inventor and Cibiltech founding partner.
“CareDx has taken another step towards bringing big data solutions to transplant patients,” said Peter Maag, CEO of CareDx. “With OTTR providing data infrastructure and with iBox providing prognostic information, we are beginning to assemble new and important solutions for caregivers that are based on artificial intelligence.”
About CareDx CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.caredx.com.
Forward Looking StatementsThis press release includes forward-looking statements, including statements regarding the Company’s partnership with Cibiltech. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including the risk that the partnership with Cibiltech does not produce the anticipated results; risks related to the development and commercialization of technologies; risks of unexpected costs and delays associated with the partnership; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
CareDx, Inc.Sasha KingChief Commercial Officer415firstname.lastname@example.org
Investor RelationsDavid ClairIntegrated Corporate Relations, Inc.email@example.com